Scarica l'app Stockscreener
10.01
0.79%
-0.08
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché TNXP Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$10.09
Aprire:
$10.18
Volume 24 ore:
466.32K
Relative Volume:
0.93
Capitalizzazione di mercato:
$159.57M
Reddito:
$13.11M
Utile/perdita netta:
$-124.02M
Rapporto P/E:
-0.7019
EPS:
-14.261
Flusso di cassa netto:
$-107.25M
1 W Prestazione:
+1.32%
1M Prestazione:
-21.55%
6M Prestazione:
-41.94%
1 anno Prestazione:
-73.43%
Intervallo 1D:
$9.58
$10.21
Intervallo di 1 settimana:
$9.40
$10.58
Portata 52W:
$9.40
$69.97
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
Nome
Tonix Pharmaceuticals Holding Corp
Settore
Industria
Telefono
212-980-9155
Indirizzo
200 CONNELL DRIVE, SUITE 3100, BERKELEY HEIGHTS, NY
Compare TNXP vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
10.01 | 165.31M | 13.11M | -124.02M | -107.25M | -14.26 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-04-18 | Iniziato | Noble Capital Markets | Outperform |
| 2019-04-18 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2017-08-18 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2016-09-07 | Downgrade | ROTH Capital | Buy → Neutral |
| 2016-02-17 | Reiterato | Oppenheimer | Outperform |
| 2015-11-04 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-06-12 | Iniziato | Oppenheimer | Outperform |
| 2015-02-17 | Reiterato | ROTH Capital | Buy |
| 2014-09-29 | Reiterato | ROTH Capital | Buy |
Mostra tutto
Tonix Pharmaceuticals Holding Corp Borsa (TNXP) Ultime notizie
Tonix Pharmaceuticals Holding Corp (TNXP) Cash Flow - TradingKey
Tonix Pharmaceuticals Holding Corp - TradingKey
Tonix Pharmaceuticals Holding Corp (TNXP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Tonix Pharmaceuticals Holding Corp. to Host Second Quarter 2026 Financial Results Conference Call and Webcast - Quiver Quantitative
Tonix to discuss second-quarter results on Aug. 10 call - Stock Titan
TNXP|Tonix Pharmaceuticals Holding Corp|Price:10.390|Chg%:+0.510 - TradingKey
Tonix Pharmaceuticals Holding Corp (TNXP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Tonix Pharmaceuticals Holding Corp. Revenue Breakdown – NASDAQ:TNXP - TradingView
Why TNXP Stock Is Suddenly Back On Retail Radar - Stocktwits
Tonix Pharmaceuticals Holding Corp (TNXP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Tonix Pharmaceuticals Holding Corp (TNXP) Institutional Confidence - TradingKey
Tonix Pharmaceuticals Holding Corp (TNXP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TNXP Slips After Hours On Slower Than Expected Launch For Fibromyalgia Drug - Stocktwits
Total debt per share of Tonix Pharmaceuticals Holding Corp. – GETTEX:TPM0 - TradingView
TNXP Stock Dives For Four Straight Sessions — Retail Eyes Drug Pipeline Payoff - Stocktwits
Tonix shares TNX-4800 Lyme disease prevention presentation - Bitget
Tonix Pharmaceuticals (TNXP) Investor presentation Summary - Quartr
Tonix Pharmaceuticals (NASDAQ:TNXP): Can This Penny Stock Deliver? - Kalkine Media
Tonix Pharmaceuticals Announces Publication in the Peer-Reviewed Journal of Virology Assessing Virulence of the 2022 Outbreak Strain of Mpox in New Animal Models - Sahm
Tonix Pharmaceuticals Announces Publication in the - GlobeNewswire
Precision Trading with Tonix Pharmaceuticals Holding Corp. (TNXP) Risk Zones - Stock Traders Daily
symbol__ Stock Quote Price and Forecast - CNN
Tonix secures Medicare coverage for fibromyalgia drug TONMYA By Investing.com - Investing.com South Africa
Tonix Pharmaceuticals (TNXP) Expands Medicare Coverage for Fibro - GuruFocus
Tonix Expands TONMYA Medicare Coverage with New Payer Agreement (TNXP) - Yahoo Finance
Tonix Pharmaceuticals Secures Major Medicare Deal for TONMYA®, Expanding Fibromyalgia Treatment Access to 145 Million Covered Lives – Minichart - Minichart
Tonix Pharmaceuticals (TNXP) Secures Medicare Coverage for Tonmy - GuruFocus
Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA® - The Manila Times
Tonix Pharmaceuticals Adds Medicare Part D Coverage for TONMYA, Expands Sales Force - TradingView
Tonix secures Medicare coverage for fibromyalgia drug TONMYA - Investing.com
Tonix Pharmaceuticals Announces Major Medicare Coverage Agreement for TONMYA, Expanding U.S. Access to Approximately 145 Million Covered Lives - Quiver Quantitative
Tonix Pharmaceuticals (NASDAQ: TNXP) secures PBM Medicare pact, targeting 145M TONMYA covered lives - Stock Titan
Form 4 Tonix Pharmaceuticals Holding Corp For: 9 July By Investing.com - Investing.com Nigeria
Tonix (NASDAQ: TNXP) CFO adds 1,453 shares through 2025 employee stock plan - Stock Titan
Technical Reactions to TNXP Trends in Macro Strategies - Stock Traders Daily
Tonix: 'Hold' Based On Tonmya Payer Expansions And MDD Trial Initiation - Seeking Alpha
Tonix Pharmaceuticals Holding Corp. has enrolled the first patient in its Phase 2 “HORIZON” study of TNX-102 SL (sublingual tablet) for the treatment of major depressive disorder (MDD). - Bitget
Tonix Pharmaceuticals Holding Corp Azioni (TNXP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Tonix Pharmaceuticals Holding Corp Azioni (TNXP) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Stillwell Richard Newcomb | Director |
Jun 08 '26 |
Buy |
11.65 |
5,000 |
58,250 |
5,000 |
| LEDERMAN SETH | Chief Executive Officer |
Jun 09 '26 |
Buy |
11.79 |
5,000 |
58,950 |
9,005 |
| LEDERMAN SETH | Chief Executive Officer |
Mar 31 '26 |
Buy |
12.62 |
5,000 |
63,100 |
20,001 |
| LEDERMAN SETH | Chief Executive Officer |
Mar 18 '26 |
Buy |
14.89 |
15,000 |
223,350 |
15,001 |
| Taylor Carolyn E. | Director |
Aug 21 '25 |
Buy |
36.03 |
418 |
15,061 |
418 |
| Treco James | Director |
Aug 20 '25 |
Buy |
36.00 |
250 |
9,000 |
250 |
2.44%
0.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):